French pharmaceutical giant Sanofi has announced its agreement to acquire Blueprint Medicines Corp. in a transaction valued at approximately $9.1 billion. This move aligns with Sanofi’s strategic objective to bolster its presence in the field of immunology, particularly focusing on rare diseases. Sanofi has agreed to pay $129 per share in cash for the U.S.-based biotech company, reflecting a 27% premium over Blueprint’s most recent closing price.
Blueprint Medicines is known for its pipeline of experimental therapies targeting immunological conditions, as well as a commercialized treatment for a rare disease. This acquisition is consistent with Sanofi’s declared ambitions to transform into a leader in immunology. Earlier in the year, Sanofi also agreed to acquire a promising antibody drug for up to $1.9 billion, highlighting its commitment to expanding its therapeutic portfolio.
For further details on this acquisition, visit the full article on Bloomberg.